Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.
about
BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseasesA multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomasBAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesotheliomaSystemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesotheliomaGenes associated with prognosis after surgery for malignant pleural mesothelioma promote tumor cell survival in vitro.Overview of the biochemical and genetic processes in malignant mesothelioma.Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma.Chemotherapy options and new advances in malignant pleural mesothelioma.In Vitro and In Vivo Antitumor Activity of [Pt(O,O'-acac)(γ-acac)(DMS)] in Malignant Pleural MesotheliomaMammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids.Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis.Expression of cancer-associated molecules in malignant mesotheliomaNew diagnostic and molecular characteristics of malignant mesothelioma.Future developments in the management of malignant pleural mesothelioma.Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research.The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistanceMicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications.The endoplasmic reticulum mitochondrial calcium cross talk is downregulated in malignant pleural mesothelioma cells and plays a critical role in apoptosis inhibition.SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesotheliomaCell type specificity of signaling: view from membrane receptors distribution and their downstream transduction networks.Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy.Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure.Role of thioredoxin-1 in apoptosis induction by alpha-tocopheryl succinate and TNF-related apoptosis-inducing ligand in mesothelioma cells.A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance.Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial.Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma
P2860
Q27851697-803EF3F5-8673-4633-B0E5-2C6076FACA89Q28389566-C9A0B8C5-00C9-40DF-9110-31937B241FC0Q28392105-E4ECB2BA-BF9F-46DD-9E37-E4B2D4509E12Q28533736-DE96DF6C-0873-43A3-903B-3E6E45C0F829Q33834736-6C5E0469-04D2-4FEE-A8B9-874F5069FEEFQ33899105-45A2B47C-E218-45A0-9584-125162D978B4Q34360248-B7391301-BA49-4D07-995D-1B6C5060A820Q35959234-4E932FD3-CE14-448E-8640-C61BA338C32FQ36022779-FDB1073A-8C0B-4F00-94AA-17562F2E62E4Q36180331-D3C9F7E8-2C7C-4CF9-9FC6-ED61E343D0B7Q36741548-9C41BE75-62F5-4D67-B2AA-9ECB382E0FFAQ37259632-77CC929B-7CAE-45E8-8A9C-3164AB860E63Q37281015-4E2DE622-7EE9-48D7-859B-63E7EFA075E3Q37360580-F49129FB-E517-4906-A48F-F4295A6DC3DCQ37449036-00E63007-EF8A-4E13-8052-E0E0C0886107Q37833952-622CB6FF-5CC7-4C60-B844-82F32597B557Q38347433-F9BE3D30-EEC0-4125-BE5C-D0BBBB0C21F5Q38509951-0C774AFD-4C1B-43D9-8AFB-4EAE943AFD1BQ38855303-57D38BA7-1FF1-4FF4-BCCE-493AF21E3194Q39123760-F7A76E7D-9A39-446C-8B3C-3E8C28B50365Q39313461-8805F6A7-0F76-4605-97EE-4DE84EBDC4E0Q39741953-8B275506-96D0-4CD6-A925-27FE18047877Q39831596-01844DB2-2048-4DD3-BB13-54B08ADED54CQ40286029-8CDB4541-6E92-4218-9F69-73E998589FFFQ42575346-F70DFB4D-C2F1-4285-BCFF-BC0AF8AACB16Q49996923-0B126B1F-978A-46C1-AC49-6AD95314FA7AQ52579899-35174EA4-BE60-4BDE-A1C1-4AF69DCB9840Q58778161-1E773E15-4F57-41BC-AF4D-F8155B259B11
P2860
Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Defective core-apoptosis signa ...... or effective drug development.
@ast
Defective core-apoptosis signa ...... or effective drug development.
@en
type
label
Defective core-apoptosis signa ...... or effective drug development.
@ast
Defective core-apoptosis signa ...... or effective drug development.
@en
prefLabel
Defective core-apoptosis signa ...... or effective drug development.
@ast
Defective core-apoptosis signa ...... or effective drug development.
@en
P1433
P1476
Defective core-apoptosis signa ...... or effective drug development.
@en
P2093
Dean A Fennell
Robin M Rudd
P304
P356
10.1016/S1470-2045(04)01492-5
P577
2004-06-01T00:00:00Z